Foundation Medicine and Flatiron Health Collaborate to Develop First-in-Class Data Platform to Accelerate Precision Medicine for Cancer

Joint effort to create unique genomic and clinical outcomes information solution to inform and accelerate development of targeted therapies to advance patient care

CAMBRIDGE, MA & NEW YORK, NY, December 2, 2014

Foundation Medicine, Inc., and Flatiron Health today announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.

This collaboration integrates the OncoCloud™ platform with Foundation Medicine’s comprehensive genomic profiling capabilities to support evidence-based drug development and help accelerate the delivery of safe, effective and targeted new cancer therapies to patients.

“Flatiron Health and Foundation Medicine share a common belief that integrated clinical and molecular information can drive a revolution in how patients battling cancer can be treated,” said Nat Turner, co-founder and CEO, Flatiron Health. “Together, Foundation Medicine and Flatiron Health will bring our collective expertise in oncology, informatics and technology to develop a first-in-class platform that helps advance cancer care.”

Foundation Medicine and Flatiron Health will work together to co-develop products based on a comprehensive, HIPAA-compliant information platform that seamlessly analyzes and integrates clinical treatment and outcome data with matched comprehensive genomic profiling data for patients who have undergone testing with FoundationOne® or FoundationOne Heme. Life science companies will be able to utilize this cloud-based platform to enable better selection of molecular candidates, more efficient clinical trial design and faster patient recruitment into clinical trials.

“The marriage of information analytics and cancer genomics represents one of the most powerful opportunities to redefine and reshape the way cancer drugs are developed and delivered to patients in need,” said Michael J. Pellini, MD, president and CEO of Foundation Medicine. “The jointly developed information products born from this collaboration will provide life science companies with a powerful new tool to access actionable data that informs the development of targeted new cancer therapies. We believe this collaboration embodies the future of cancer drug development and delivery, and we are delighted to partner with Flatiron to make the future of cancer care a reality today.”


About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and certain pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

About Flatiron

Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. @FlatironHealth